リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Comparison of the New Neo-Glasgow Prognostic Score Based on the Albumin-Bilirubin Grade with Currently Used Nutritional Indices for Prognostic Prediction following Surgical Resection of Hepatocellular Carcinoma : A Multicenter Retrospective Study in Japan」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Comparison of the New Neo-Glasgow Prognostic Score Based on the Albumin-Bilirubin Grade with Currently Used Nutritional Indices for Prognostic Prediction following Surgical Resection of Hepatocellular Carcinoma : A Multicenter Retrospective Study in Japan

KAIBORI Masaki 0000-0002-0577-3921 HIRAOKA Atsushi 0000-0003-1989-0480 IIDA Hiroya 30733901 0000-0001-6245-4583 KOMEDA Koji HIROKAWA Fumitoshi UENO Masaki KOSAKA Hisashi 0000-0002-2926-9973 MATSUI Kousuke SEKIMOTO Mitsugu 0000-0003-2184-538X 滋賀医科大学

2022.04.20

概要

Simple Summary:
Clinical usefulness of the recently developed neo-Glasgow prognostic score (GPS) as a nutritional prognostic assessment in hepatocellular carcinoma (HCC) were evaluated in a multicenter retrospective study. In multivariate analysis with the Cox proportional hazards model, elevated alpha-fetoprotein (AFP; ≥100 ng/mL; hazard ratio [HR] 2.190, p < 0.001), multiple tumors (HR 1.784, p = 0.006), tumor size of ≥5 cm (HR 1.508, p = 0.032), and neo-GPS of ≥1 (HR 1.554, p = 0.019) were significant prognostic factors for OS, whereas elevated AFP (≥100 ng/mL) (HR 1.743, p < 0.001), multiple tumors (HR 1.537, p = 0.004), and neo-GPS of ≥1 (HR 1.522, p = 0.001) were significant prognostic factors for PFS. A neo-GPS of ≥1 was associated with higher rate of high-grade (≥3) Clavien-Dindo complications than a neo-GPS of <1 (31.1% vs. 16.7%, p = 0.007). Neo-GPS was a good prognostic nutritional assessment tool for the prediction of postoperative complications and prognosis in patients undergoing surgical HCC resection.
Abstract:
Nutritional assessment is important for predicting a prognosis in hepatocellular carcinoma (HCC). The authors examined the utility of the recently developed neo-Glasgow prognostic score (GPS) as a nutritional prognostic assessment in HCC in a multicenter retrospective study of 271 patients with HCC and Child-Pugh class A liver function who underwent R0 resection between 2011 and 2013. The median age was 72 years, 229 and 42 patients had Child-Pugh scores of 5 and 6, respectively, 223 patients had single tumors, the median tumor size was 3.6 cm, and open and laparoscopic resection were performed in 138 and 133 patients, respectively. We compared the prognostic predictive utility of the prognostic nutritional index, neutrophil/lymphocyte and platelet/lymphocyte ratios, controlling nutritional status score, GPS, and neo-GPS, which uses albumin-bilirubin grade (ALBI) instead of albumin. The c-indexes for the predictive prognostic value for overall survival (OS) and progression-free survival (PFS) were best for neo-GPS (OS: 0.571 vs. ≤0.555; PFS: 0.555 vs. ≤0.546). In multivariate analysis with the Cox proportional hazards model, elevated alpha-fetoprotein (AFP; ≥100 ng/mL; hazard ratio [HR] 2.190, 95% confidence interval [CI] 1.493–3.211, p < 0.001), multiple tumors (HR 1.784, 95%CI 1.178–2.703, p = 0.006), tumor size of ≥5 cm (HR 1.508, 95%CI 1.037–2.193, p = 0.032), and neo-GPS of ≥1 (HR 1.554, 95%CI 1.074–2.247, p = 0.019) were significant prognostic factors for OS, whereas elevated AFP (≥100 ng/mL) (HR 1.743, 95%CI 1.325–2.292, p < 0.001), multiple tumors (HR 1.537, 95%CI 1.148–2.057, p = 0.004), and neo-GPS of ≥1 (HR 1.522, 95%CI 1.186–1.954, p = 0.001) were significant prognostic factors for PFS. A neo-GPS of ≥1 was associated with a higher rate of high-grade (≥3) Clavien-Dindo complications than a neo-GPS of <1 (31.1% vs. 17.0%, p = 0.007). Neo-GPS was a good prognostic nutritional assessment tool for the prediction of postoperative complications and prognosis in patients undergoing surgical HCC resection.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 2001, 94, 153–156. [CrossRef] [PubMed]

2. Onodera, T.; Goseki, N.; Kosaki, G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi 1984, 85, 1001–1005, (Abstract in English). [PubMed]

3. Broggi, M.S.; Patil, D.; Baum, Y.; Nieh, P.T.; Alemozaffar, M.; Pattaras, J.G.; Ogan, K.; Master, V.A. Onodera’s prognostic nutritional index as an independent prognostic factor in clear cell renal cell carcinoma. Urology 2016, 96, 99–105. [CrossRef] [PubMed]

4. Motomura, T.; Shirabe, K.; Mano, Y.; Muto, J.; Toshima, T.; Umemoto, Y.; Fukuhara, T.; Uchiyama, H.; Ikegami, T.; Yoshizumi, T.; et al. Neutrophil–lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J. Hepatol. 2013, 58, 58–64. [CrossRef] [PubMed]

5. Kinoshita, A.; Onoda, H.; Imai, N.; Iwaku, A.; Oishi, M.; Fushiya, N.; Koike, K.; Nishino, H.; Tajiri, H. Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. Br. J. Cancer 2012, 107, 988–993. [CrossRef]

6. Ignacio de Ulíbarri, J.; González-Madroño, A.; de Villar, N.G.; González, P.; González, B.; Mancha, A.; Rodríguez, F.; Fernández, G. CONUT: A tool for controlling nutritional status. First validation in a hospital population. Nutr. Hosp. 2005, 20, 38–45.

7. Forrest, L.M.; McMillan, D.C.; McArdle, C.S.; Angerson, W.J.; Dunlop, D.J. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br. J. Cancer 2003, 89, 1028–1030. [CrossRef]

8. Elahi, M.M.; McMillan, D.C.; McArdle, C.S.; Angerson, W.J.; Sattar, N. Score based on hypoalbuminemia and elevated C-reactive protein predicts survival in patients with advanced gastrointestinal cancer. Nutr. Cancer 2004, 48, 171–173. [CrossRef]

9. Crumley, A.B.; McMillan, D.C.; McKernan, M.; McDonald, A.C.; Stuart, R.C. Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br. J. Cancer 2006, 94, 637–641. [CrossRef]

10. Shimoda, Y.; Fujikawa, H.; Komori, K.; Watanabe, H.; Kano, K.; Yamada, T.; Shiozawa, M.; Morinaga, S.; Katsumata, K.; Tsuchida, A.; et al. Preoperative utility of the Glasgow prognostic score on outcomes of patients with locally advanced gastric cancer. J. Gastrointest. Cancer 2021. [CrossRef]

11. Kaibori, M.; Hiraoka, A.; Matsui, K.; Matsushima, H.; Kosaka, H.; Yamamoto, H.; Yamaguchi, H.; Yoshida, K.; Sekimoto, M. Predicting complications following surgical resection of hepatocellular carcinoma using newly developed neo-Glasgow prognostic score with ALBI grade: Comparison of open and laparoscopic surgery cases. Cancers 2022, 14, 1402. [CrossRef] [PubMed]

12. Hiraoka, A.; Kato, M.; Marui, K.; Murakami, T.; Onishi, K.; Adachi, T.; Matsuoka, J.; Ueki, H.; Yoshino, T.; Tsuruta, M.; et al. Easy clinical predictor for low BCAA to tyrosine ratio in chronic liver disease patients with hepatocellular carcinoma: Usefulness of ALBI score as nutritional prognostic marker. Cancer Med. 2021, 10, 3584–3592. [CrossRef] [PubMed]

13. Pugh, R.N.; Murray-Lyon, I.M.; Dawson, J.L.; Pietroni, M.C.; Williams, R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg 1973, 60, 646–649. [CrossRef] [PubMed]

14. Johnson, P.J.; Berhane, S.; Kagebayashi, C.; Satomura, S.; Teng, M.; Reeves, H.L.; O’Beirne, J.; Fox, F.; Skowronska, A.; Palmer, D.; et al. Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach- the ALBI grade. J. Clin. Oncol. 2015, 33, 550–558. [CrossRef]

15. Hiraoka, A.; Kumada, T.; Michitaka, K.; Toyoda, H.; Tada, T.; Ueki, H.; Kaneto, M.; Aibiki, T.; Okudaira, T.; Kawakami, T.; et al. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2016, 31, 1031–1036. [CrossRef]

16. The Liver Cancer Study Group of Japan. The General Rules for The Clinical and Pathological Study of Primary Liver Cancer, 6th ed.; Kanehara: Tokyo, Japan, 2015; p. 26.

17. Kokudo, N.; Takemura, N.; Hasegawa, K.; Takayama, T.; Kubo, S.; Shimada, M.; Nagano, H.; Hatano, E.; Izumi, N.; Kaneko, S.; et al. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol. Res. 2019, 49, 1109–1113. [CrossRef]

18. Strasberg, S.M.; Belghiti, J.; Clavien, P.A.; Gadzijev, E.; Garden, J.O.; Lau, W.Y.; Makuuchi, M.; Strong, R.W. The Brisbane 2000 terminology of liver anatomy and resections. HPB 2000, 2, 333–339. [CrossRef]

19. Couinaud, C. Le Foie: Études Anatomiques et Chirurgicales; Masson: Paris, France, 1957.

20. Dindo, D.; Demartines, N.; Clavien, P.A. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann. Surg 2004, 240, 205–213. [CrossRef]

21. Kanda, Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013, 48, 452–458. [CrossRef]

22. Hiraoka, A.; Michitaka, K.; Kumada, T.; Izumi, N.; Kadoya, M.; Kokudo, N.; Kubo, S.; Matsuyama, Y.; Nakashima, O.; Sakamoto, M.; et al. Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in Japan: The need for a more detailed evaluation of hepatic function. Liver Cancer 2017, 6, 325–336. [CrossRef]

23. Hiraoka, A.; Kumada, T.; Kudo, M.; Hirooka, M.; Tsuji, K.; Itobayashi, E.; Kariyama, K.; Ishikawa, T.; Tajiri, K.; Ochi, H.; et al. Albumin-bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology: A comparison with the liver damage and Child-Pugh classifications. Liver Cancer 2017, 6, 204–215. [CrossRef] [PubMed]

24. Shrotriya, S.; Walsh, D.; Bennani-Baiti, N.; Thomas, S.; Lorton, C. C-reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: A systematic review. PLoS ONE 2015, 10, e0143080. [CrossRef] [PubMed]

25. Yoshiji, H.; Nagoshi, S.; Akahane, T.; Asaoka, Y.; Ueno, Y.; Ogawa, K.; Kawaguchi, T.; Kurosaki, M.; Sakaida, I.; Shimizu, M.; et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res. 2021, 51, 725–749. [CrossRef] [PubMed]

26. Yoshiji, H.; Nagoshi, S.; Akahane, T.; Asaoka, Y.; Ueno, Y.; Ogawa, K.; Kawaguchi, T.; Kurosaki, M.; Sakaida, I.; Shimizu, M.; et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. J. Gastroenterol. 2021, 56, 593–619. [CrossRef]

27. Kaido, T.; Ogawa, K.; Fujimoto, Y.; Ogura, Y.; Hata, K.; Ito, T.; Tomiyama, K.; Yagi, S.; Mori, A.; Uemoto, S. Impact of sarcopenia on survival in patients undergoing living donor liver transplantation. Am. J. Transplant. 2013, 13, 1549–1556. [CrossRef]

28. Chang, K.V.; Chen, J.D.; Wu, W.T.; Huang, K.C.; Hsu, C.T.; Han, D.S. Association between loss of skeletal muscle mass and mortality and tumor recurrence in hepatocellular carcinoma: A systematic review and meta-analysis. Liver Cancer 2018, 7, 90–103. [CrossRef]

29. Hiraoka, A.; Michitaka, K.; Ueki, H.; Kaneto, M.; Aibiki, T.; Okudaira, T.; Kawakami, T.; Yamago, H.; Suga, Y.; Tomida, H.; et al. Sarcopenia and two types of presarcopenia in Japanese patients with chronic liver disease. Eur. J. Gastroenterol. Hepatol. 2016, 28, 940–947. [CrossRef]

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る